Our production units in Kishanpura, Nalagarh (Himachal Pradesh, India) and Kalyani (Near Kolkata, West Bengal, India) are both state-of-art manufacturing facilities equipped with most modern infrastructure, machinery, technologies, large installed capacity and stringent quality and safety standards in every phase and part of the production activity.

The pharmaceutical market has advanced significantly, and it is now our goal to provide high-quality APIs in the field of oncology. We aim to acquire and possess the finest technology to ensure the manufacture of world class finished products at competitive prices. In our pursuit to manufacture the best quality APIs, we stay fully committed to our responsibilities toward safety, health and the environment.  

Kalyani Unit

Fresenius Kabi Oncology Limited manufactures oncological and non-oncological APIs at its state-of-the-art facility in Kalyani, near Kolkata (West Bengal) maintaining the highest levels of international quality and GMP standards, while ensuring high productivity and cost competitiveness. We have invested heavily in upgrading our facilities at Kalyani into a modern API Production Site in line with international quality standards and equipped to meet intensive requirement of Occupational Health and Safety Standards.

Key Manufacturing Capabilities & Attributes:

●      Leading manufacturer of key anti-cancer APIs.

●      One of the largest API manufacturers in the world for Paclitaxel & Irinotecan.

●      Major supplier to leading generic companies across the globe.

●      Strict control of Quality & GMP.

●      Guaranteed supplies and proven track record of meeting customers’ requirements.

Our Kalyani Plant is currently approved by Authorities like EUDRA GMP (Europe), TGA and COFEPRIS (Mexico), ANVISA(Brazil).

Kishanpura Unit :

The Sterile Injectables facility of Fresenius Kabi Oncology Limited is located at Kishanpura, Nalagarh in Himachal Pradesh.  This state-of-the-art facility is equipped with modern infrastructure and trained manpower for carrying out the processes meeting the international regulatory standards.   

The plant has dedicated buildings for non-cytotoxic and cytotoxic products and is engaged in the production of Liquid and Lyophilized injectables.  Technology involved for manufacturing of sterile injectables includes both aseptic filtration/filling and terminal sterilization.

Full consideration has been given to the aspect of containment by extensive usage of closed Restricted Access Barrier Systems (cRABS) and Isolator technology.  Kishanpura, Nalagarh Plant is currently approved by authorities like EMA, ANVISA, Health Canada and Russian Health Authority and its products have regulatory approvals in more than 30 countries across the world.

We remain committed to the Fresenius Kabi’s philosophy of “Advancing Patient Care” by providing the best products from our most modern manufacturing facility to the patients.